



**HAL**  
open science

# Narrative Review of the Relationship Between CKD and Diabetic Foot Ulcer

Jean-Baptiste Bonnet, Ariane Sultan

► **To cite this version:**

Jean-Baptiste Bonnet, Ariane Sultan. Narrative Review of the Relationship Between CKD and Diabetic Foot Ulcer. *Kidney International Reports*, 2022, 7 (3), pp.381-388. 10.1016/j.ekir.2021.12.018 . hal-03602629

**HAL Id: hal-03602629**

**<https://hal.science/hal-03602629v1>**

Submitted on 9 Mar 2022

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution 4.0 International License

# Narrative Review of the Relationship Between CKD and Diabetic Foot Ulcer

Jean-Baptiste Bonnet<sup>1,2</sup> and Ariane Sultan<sup>1,3</sup>

<sup>1</sup>Transversal Nutrition Unit, Endocrinology-Diabetes-Nutrition Department, University Hospital of Montpellier, Montpellier, France; <sup>2</sup>Mixed Research Unit (UMR) 1302, Institute Desbrest of Epidemiology and Public Health, University of Montpellier, Institut National de la Santé et de la Recherche Médicale, University Hospital of Montpellier, Montpellier, France; and <sup>3</sup>Phy-MedExp, University of Montpellier, Institut National de la Santé et de la Recherche Médicale U1046, Centre National de la Recherche Scientifique Mixed Research Unit (UMR) 9214, Montpellier, France

Diabetic foot ulcer (DFU) and chronic kidney disease (CKD) are 2 significant complications of diabetes mellitus (DM). Up to 40% of patients with DM are expected to also develop CKD, and 19% to 34% will suffer from DFU during their lifetimes. However, data on the link between podiatric risk and the extent of CKD are scarce. Neuropathy, a key element of the International Working Group on the Diabetic Foot (IWGDF) classification, nevertheless appears to be related to the CKD stage. The incidence of DFU and its poor evolution also appear to be linked to the stage of CKD, with mortality reaching its peak in patients with end-stage renal disease (ESRD). Whatever, the decrease in the rate of diabetic foot amputation observed worldwide, especially for major amputations, is also observed in patients with ESRD. Specific actions taken for patients undergoing dialysis seems to improve the DFU prognosis. CKD and DFU share a number of elements of pathophysiology, the first of which is peripheral arterial disease (PAD). Uremic neuropathy and nutritional status also seem to create a link between the development of the 2 complications. This literature review provides an update on the complex and dynamic relationship between DFU and CKD. It examines the epidemiologic link between CKD and diabetic foot risk, CKD and DFU occurrence, and CKD and DFU prognosis. It focuses on the pathophysiological links between these 2 complications. Finally, it highlights the actions taken to improve management in the ESRD population that have reduced the rate of major amputations in this population by more than half.

**DM** is a chronic metabolic disease, often complicated by micro- and macrovascular disorders. At the junction of neuropathic and vascular disorders, DFU, usually referred to as “diabetic foot,” stands out as a major complication of DM.<sup>1</sup> Diabetic foot is a prominent public health issue. In 2013, a study by the French National Institute of Health Monitoring (Institut National de Veille Sanitaire) evaluated the incidence of hospitalizations for foot wounds and amputations at 668 per 100,000, with 25 per 100,000 for people with diabetes.<sup>2</sup> Furthermore, it is important to note that the incidence of hospitalizations for foot injury of potentially active subjects 50 to 55 years old (600 per 100,000 people) is roughly of the same magnitude, with potential social and functional consequences. Ultimately,

19% to 34% of patients with diabetes will suffer from foot ulcer during their lifetimes,<sup>1</sup> making diabetes still the leading cause of nontraumatic amputation. Essentially, patients with diabetes have a 12.3-fold risk of undergoing amputation surgery,<sup>3</sup> which is correlated with a huge mortality rate. According to Larsson *et al.*,<sup>4</sup> the mortality rate at 1 year and 5 years after amputation is 15% and 69%, respectively. Gök *et al.*<sup>5</sup> found a 5-year mortality rate of 70% in a study in which age and sex had no significant impact on the mortality rate.

The medical impact of DFU has thus led to the creation of the IWGDF. In 1999, IWGDF guidelines stratified patients with diabetes into 4 groups in relation to the relative risk of DFU incidence.<sup>6</sup> The classification is as follows: no evidence of neuropathy or peripheral vascular disease (category 0); neuropathy or peripheral vascular disease present but no evidence of foot deformity (category 1); 2 out of the following: foot deformation, lower extremity arteriopathy, or neuropathy (category 2); and history of foot ulcer or lower extremity amputation (category 3). This risk gradation is internationally recognized by health agencies. In

---

**Correspondence:** Jean-Baptiste Bonnet, Unité Transversale de Nutrition, Département Nutrition Endocrinologie Diabète, Hôpital Lapeyronie, 191 avenue du doyen Gaston Giraud 34295 Montpellier, France. E-mail: [jean-baptiste-bonnet@chu-montpellier.fr](mailto:jean-baptiste-bonnet@chu-montpellier.fr)

addition, the National Institute for Health and Care Excellence has established a similar gradation but with 3 levels: low, intermediate, and high risk. National Institute for Health and Care Excellence's scoring system has led to the recommendations in the Anglo-Saxon medical world.<sup>7</sup> Since 2019, the IWGDF has stated that patients with diabetes with ESRD should be classified as category 3 in podiatric risk<sup>8</sup> even with no history of foot ulcer or lower extremity amputation, on the basis of the observation that patients with diabetes undergoing hemodialysis have a higher risk of developing DFU with a poorer prognosis than other patients with diabetes.<sup>9</sup> The National Institute for Health and Care Excellence committee had come to the same conclusion in 2015.<sup>7</sup> Thus, this modification in the IWGDF and National Institute for Health and Care Excellence guidelines highlights a relationship between DFU and CKD. The aim of this work was therefore to review the literature on the link between CKD and DFU. Epidemiology, prognosis, physiopathology, and the link between the IWGDF classification with its components and CKD are discussed.

### CKD and DFU: The Physiopathological Link

It is important to note that diabetes is not the only cause of foot ulcer in patients with renal failure<sup>10</sup>: arterial disease and/or nondiabetic neuropathy can lead to distal ulceration, independently of any diabetes.<sup>11</sup>

#### PAD and CKD

It is not surprising that PAD is a link between ESRD and diabetic foot. In the follow-up phase of the study by Morbach *et al.*,<sup>12</sup> patients with DFUs had the same long-term survival prognosis if they were on dialysis or had PAD without ESRD. Furthermore, patients with PAD and on dialysis did not have a poorer evolution of DFU than those with only PAD. In this study, dialysis seemed to have had an effect on DFU only through its inflammatory action on the vascular system. This observation is quite similar to those of other studies on patients undergoing dialysis,<sup>13</sup> even when autonomic neuropathy seems to intervene in the physiopathology of DFU.<sup>14</sup> In addition, the link between CKD and PAD is well known.<sup>15</sup> DM is already associated with a higher risk of PAD in the population of patients with an eGFR <30 ml/min per 1.73 m<sup>2</sup>.<sup>16</sup> Furthermore, an eGFR <30 ml/min per 1.73 m<sup>2</sup> is a risk factor for atherosclerosis and PAD,<sup>17</sup> and likewise, a high prevalence of PAD, considered as an ankle-brachial index <0.9, was demonstrated in nondialyzed patients with CKD.<sup>18</sup> Moreover, the physiological links between oxidative stress and PAD and between oxidative stress and CKD are well known. Yilmaz *et al.*<sup>19</sup> examined a cohort of patients without diabetes and highlighted this progressive accumulation of

asymmetric dimethylarginine ( $P < 0.001$ ), with a possible participation of zinc and selenium deficiency and the known participation of hyperphosphatemia in CKD.<sup>20</sup> Finally, Margolis *et al.*<sup>21</sup> pointed to the histologic similarities between mesangial alteration and fibroblasts or podocytes damaged by hyperglycemia. Thus, diabetic nephropathy and PAD are quite the same disease. Nowadays, successful revascularization seems to provide good results in improving the prognosis of DFU patients with ESRD,<sup>22</sup> and older results need to be reconsidered within the context of today's improved techniques.

Yet, these observations do not necessarily match with the results of Game's quite old observation that DFU is temporally associated with dialysis initiation.<sup>23</sup> Ndip *et al.*<sup>24</sup> made a similar observation. Is end-stage renal failure accelerated by the inflammatory component of foot ulcer?<sup>25</sup> Is dialysis treatment initiation the tipping point of renal end-stage failure, through the per-dialytic vascular exploitation on an already precarious vascular background in patients with DM? Indeed, one of the major and immediate effects of dialysis is the intradialytic drop in microvascular blood flow. Intradialytic drop seems to be steeper during dialysis sessions in the diabetic population<sup>26</sup> versus nondiabetic population.<sup>27</sup> This issue merits further research.

#### Uremic Neuropathy

One factor that has been explored as a link between DFU and ESRD is neuropathic aggravation through the hyperuremia due to renal failure.<sup>28</sup> Uremia is known to be an independent cause of neuropathy in ESRD,<sup>29</sup> and nondiabetic neuropathy seems to be correlated with the level of serum creatinine.<sup>30</sup> Thus, hyperuremia might worsen preexisting peripheral neurologic disease, affecting wound healing<sup>31</sup> and promoting infection.<sup>32</sup> Furthermore, according to the observation of Laaksonen *et al.*,<sup>33</sup> uremic neuropathy in patients with diabetes does not seem to be improved by dialysis, even though the improvement in patients without diabetes is not a consensus.<sup>34</sup>

#### Nutritional Status and CKD

However, the patient's overall history should not be overlooked in the management of DFU. Indeed, nutritional status is a central factor in wound healing in general, in DFU,<sup>35</sup> and in infection for DFU prognosis.<sup>36</sup> While the link between eGFR and zinc and selenium deficiency has been mentioned,<sup>19</sup> CKD's role in altering the levels of vitamins such as vitamin C<sup>37</sup> and arginine<sup>38</sup> has been emphasized. Hence, the role of zinc and other trace elements in wound healing should be kept in mind.<sup>39</sup> In parallel, it is interesting to note that anemia seems to be more prevalent in patients with foot complications and CKD.<sup>40</sup>

## Global Management

Often forgotten, it is nevertheless important to recall that reaching CKD stage 4 or 5 may be a turning point in the patient's life. At this point, the nephrologist often becomes the family physician of the patient with diabetes,<sup>41</sup> and the medical community begins to consider dialysis, vascular access, ESRD dietary plans, and kidney transplant more seriously. Yet, is there still room to talk about foot care? In addition, once a patient enters a dialysis program, treatments occur at a rhythm of 3 sessions per week, which is often exhausting, with increases in anxiety<sup>42</sup> and their impact on mortality.<sup>43</sup> As a dialysis program is very time consuming, is there still a place for regular consultations with the podiatrist or the diabetes physician during days without dialysis? Ndip *et al.*<sup>44</sup> indeed advanced the hypothesis that the foot risk for patients under dialysis might be further aggravated by inadequate or no foot care in dialysis centers, as foot care is often not a medical priority compared with dialysis itself.

## Epidemiology

Up to 40% of patients with diabetes are expected to also develop CKD.<sup>45</sup> In 2018, according to data from the Registry of the French Epidemiological Network and Nephrology Information Network (Réseau Épidémiologique et Information en Néphrologie), the incidence rate of ESRD treated by dialysis or kidney transplantation was 142 per 100,000 people with diabetes. There are 2 incidence peaks, at 30 to 34 years old and 80 to 84 years.<sup>46</sup> In 2018, kidney replacement therapy was started for 5,025 patients with diabetes, representing 47% of the newly dialyzed population.<sup>46</sup> Thus, the review of Narres *et al.*<sup>47</sup> reported a higher relative risk of ESRD in the diabetic population compared with the nondiabetic population: between 6.2 and 62.0 times higher than in the general population.

## Risk Stratification

Data on the link between podiatric risk and the extent of CKD are scarce.<sup>48</sup> Recently, Hurley *et al.*<sup>49</sup> studied diabetic subjects recruited during consultation with a family physician and found a linear correlation between the estimated glomerular filtration rate (eGFR) and an abnormal cutaneous pressure perception assessed with a 10g monofilament, an altered vibration perception threshold, and an abnormal modified Neuropathy Disability Score. They observed a 1% increase in the odds of having an abnormal cutaneous pressure perception for each unit decrease in eGFR. Surprisingly, there was no independent association between a new foot ulceration and a reduced eGFR.<sup>49</sup> Moreover, with equal glycemic control, the prevalence of diabetic

peripheral neuropathy was higher in patients with eGFR <60 ml/min per 1.73 m<sup>2</sup> than in patients without eGFR <60 ml/min per 1.73 m<sup>2</sup>. This was also the case when the glucose time in range or glucose management indicator measured by continuous glucose monitoring was used.<sup>50</sup> However, although diabetic neuropathy is one of the key mechanisms in DFU pathophysiology, cardio autonomic neuropathy seems to independently predict the progression of diabetic nephropathy and, consequently, of CKD.<sup>14,51</sup> If this is the case, some elements of autonomic neuropathy, such as the circadian rhythms of blood pressure disorders,<sup>52</sup> should be further explored for the global management of CKD and DFU. To our knowledge, there is nevertheless no study highlighting a statistical evidence of a direct correlation between IWGDF podiatric risk and CKD, and the limitations in predictive power seem to be due to the weak relationship between some of the IWGDF components and CKD.

Furthermore, Ndip *et al.*<sup>24,53</sup> described podiatric risk repartition in a population under dialysis. Podiatric risk grades 2 and 3 were overrepresented, amounting to 80% to 90% of the population. However, the only robust study regarding the components of the IWGDF risk classification and CKD was the retrospective cohort of Otte *et al.*<sup>54</sup> A total of 669 patients who had been hospitalized 1,336 times were taken into account (539 with CKD 3, 540 with CKD 4 to 5, and 259 under dialysis treatment).<sup>54</sup> The study showed no significant differences between CKD stages for peripheral neuropathy or foot deformity but demonstrated differences in history of foot ulceration between the stages ( $P < 0.001$ ).

## DFU Risk

Aragón-Sánchez *et al.*<sup>55</sup> found a link between albuminuria (with or without impaired renal function) and DFU history. In patients with type 2 diabetes, Wolf *et al.*<sup>56</sup> demonstrated a positive correlation between creatinine level and DFU risk ( $P < 0.005$ ) in a relatively large population (4,007 patients) and, as for type 1 diabetes, with the gravity of the wound ( $P < 0.001$ ). Furthermore, analysis from patients with type 1 diabetes seemed to suggest a deterioration at 30 ml/min per 1.73 m<sup>2</sup>, but conclusions were difficult to draw with a small population.<sup>56</sup> ESRD is associated with an increased risk for DFU occurrence, and in the meta-analysis of Kaminski *et al.*,<sup>57</sup> DM represented a 3.76 (2.21–6.40) relative risk of ulceration in adults with ESRD. The different items of the IWGDF risk scale stood out as risk factors in this meta-analysis: neuropathy, PAD, history of amputation or ulcer, and foot deformity.

In the first prospective study conducted in a population of patients under dialysis, 72% of the population with a DFU was living with diabetes. While diabetes did not emerge as a risk factor in multivariate analysis, neuropathy (hazard ratio = 3.02;  $P = 0.002$ ) and a history of previous foot ulceration (hazard ratio = 2.86;  $P = 0.001$ ) were robust to multivariate analysis. Nail pathology also appeared to be predictive of first ulcer in this dialysis population in multivariate analysis. This may represent a focus for prevention.<sup>58</sup>

## DFU Prognosis

CKD is correlated with a higher amputation rate in patients with DFU.<sup>25</sup> Several studies have explored the link among ulcer, healing, amputation, and renal function. Despite a small population with type 1 diabetes, Wolf *et al.*<sup>56</sup> established a negative correlation between renal function and foot ulcer, amputation incidence and wound gravity based on the Wagner and Armstrong stages. Similarly, He *et al.*<sup>59</sup> found that healing prognosis and amputation risk were correlated with renal function stage.

In their review, Jupiter *et al.*<sup>60</sup> highlighted that CKD was an independent factor correlated with a higher mortality rate in patients with DFU. Some found that CKD and eGFR  $<60$  ml/min per  $1.73$  m<sup>2</sup> were correlated with a higher mortality rate for patients with DFU or after amputation.<sup>61</sup> Van Baal *et al.*<sup>62</sup> showed a correlation between mortality and an eGFR  $<30$  ml/min per  $1.73$  m<sup>2</sup> in this population, and Carrington *et al.*<sup>63</sup> showed a correlation between mortality and the serum creatinine level itself. However, is there a linear correlation, or is there a breaking point? It is not possible to answer this question at this point.

In addition, it is known that ESRD is associated with nontraumatic lower limb amputation.<sup>64</sup> According to Jones *et al.*,<sup>65</sup> the presence of at least 2 factors: neuropathy, arteriopathy, foot deformity, or nail pathology seems to be correlated with a poor survival index of DFU in populations on hemodialysis, but their study lacked statistical power because of a small cohort. In the meta-analysis of Kaminski *et al.*,<sup>57</sup> DM represented a 7.5 (5.15–10.87) relative risk of amputation in adults with ESRD on dialysis compared with people without diabetes. Unfortunately, the available data were largely derived from retrospective and cross-sectional studies and, therefore, have limited ability to determine temporal association between risk factors and foot disease. The Dialysis Outcomes and Practice Patterns Study showed a 9-fold greater risk of amputation in the diabetes group versus nondiabetic group,<sup>10</sup> which is quite similar to the observation in the Medicare ESRD population (odds ratio = 8.93;  $P < 0.0001$ ).<sup>66</sup>

Albuminuria is a known factor of mortality in type 2 diabetes, independently of CKD levels.<sup>67</sup> Unsurprisingly, it is also linked to the DFU prognosis<sup>55</sup> and mortality.<sup>68</sup> More extensive CKD is an independent factor for poor prognosis of DFU in terms of mortality.

CKD and eGFR  $<60$  ml/min per  $1.73$  m<sup>2</sup> are correlated with a higher mortality rate for patients with DFU.<sup>69</sup> In their review, Jupiter *et al.*<sup>60</sup> highlighted that CKD was an independent factor correlated with a higher mortality rate in patients with DFU. Van Baal *et al.*<sup>62</sup> showed a correlation between mortality and an eGFR  $<30$  ml/min per  $1.73$  m<sup>2</sup> in this population. This is concordant with Carrington *et al.*,<sup>63</sup> who showed a correlation between mortality and the serum creatinine level itself. This effect is stronger than the well-known relation between mortality and ESRD.<sup>12</sup>

## Interventions Aimed at Improving DFU Prognosis

### A Decrease in Amputation Rates

A decrease in the rate of diabetic foot amputation has been observed worldwide, especially for major amputations,<sup>10</sup> and this has been also reported for the population under dialysis. Thus, a major analysis of the United States National Registry of dialysis patients<sup>70</sup> highlighted the significant decline in the global amputation rate between 2000 and 2014. The adjusted rate of all lower extremity amputations decreased from 5.42 per 100 person-years (95% CI, 5.28–5.56) in 2000 to 2.66 per 100 person-years (95% CI, 2.59–2.72) in 2014. This is a relative decrease of 51.0% and applies to both patients with diabetes and those without, although with baseline rates significantly higher for the diabetic group. There was a decrease of 52.8% between 2000 and 2014 in the diabetic group and 48.0% in the nondiabetic group. The amputation rate changed from 8.65 per 100 person-years (95% CI, 8.41–8.88) in 2000 to 4.09 per 100 person-years (95% CI, 3.99–4.19) in 2014 in the diabetic group and from 1.43 per 100 person-years (95% CI, 1.31–1.54) to 0.74 per 100 person-years (95% CI, 0.69–0.79) in the nondiabetic group. Further analysis was completed on this same population from 2000 to 2015 by Harding *et al.*,<sup>70</sup> who highlighted a 2.8% decrease in minor amputations (toe and foot) per year (from 2.8 to 2.1 per 100 person-years) as well as a 6.4% decrease in major amputations (above knee) per year (from 5.2 to 2.5 per 100 person-years). These observations were the same for men and women and for young ( $<65$  years) and older ( $\geq 65$  years) patients. According to the data of Margolis *et al.*<sup>21</sup> for their Philadelphia cohort of patients with diabetes with neuropathic foot ulcers, the global trends between 1991 and 2000 for minor amputations (toe, forefoot, and midfoot) were modified from 2.79 per 100

person-years to 6.01. The data of this study showed that minor amputations reached 72.63% of total amputations.<sup>71</sup>

### Dialysis Unit and Foot Disease

In accordance with the US cohort, several interventional studies have suggested that specific actions taken for patients undergoing dialysis can improve outcomes.<sup>72,73</sup>

Thus, different management approaches have been implemented for high-risk populations, especially ethnic subgroups, to improve DFU management.<sup>74,75</sup> The study on the Fresenius Dialysis Centers Network in North America should be mentioned in this regard. This work showed that changes in the management of nursing care and the implementation of a foot care program provided by dedicated dialysis nurses were correlated with a 17% decrease in major limb amputations: from 1.30 per 100 person-years to 1.07 ( $P = 0.0034$ ).<sup>73</sup> As PAD is an irreversible disorder, it is important to maintain a proactive approach to podiatrist care for who underwent a kidney transplant,<sup>76</sup> especially if the risk of an unfavorable evolution of local infection under transplant immunosuppression is taken into account.

This global improvement in the amputation rate in patients with and without diabetes and the striking effect on major amputations seem to highlight the efforts of dialysis centers to implement a culture of prevention of trophic disorders and to better address vascular handling. However, despite the constant improvement in diabetic foot management, patients under dialysis still have a very poor podiatric prognosis,<sup>77</sup> and major amputations are still a common outcome. Nevertheless, the dialysis team's attention to DFU problems and changes in how they are managed might be a key<sup>78</sup> (Table 1).

### Changes in Demographic Characteristics Change the Podiatric Prognosis Unpredictably

Last, it is important to note that the characteristics of new patients under dialysis are evolving. Indeed, a recent publication based on an American cohort showed a shift in the diabetic population, with a higher proportion of women, Hispanic people, unemployed patients, and patients with higher body mass index, in addition to fewer people with cancer and chronic obstructive pulmonary disease. The impact of these epidemiologic changes on mortality or amputation are therefore quite unpredictable. Mortality and amputation will have to be monitored<sup>71</sup> because social deprivation, especially among minorities, has been shown to have a huge effect on CKD and DM.

### Conclusion

The incidence of DFU and its poor evolution appear to be proportionally related to the stage of chronic renal

**Table 1.** Checklist for a dialysis unit

Dialysis unit organization	<ul style="list-style-type: none"> <li>• Collaboration with a specialized podiatric clinic</li> <li>• A nurse referent for podiatric issues and monitoring</li> <li>• Multidisciplinary team including a podiatry</li> <li>• Consultation during dialysis sessions</li> <li>• Access to a diabetes team</li> </ul>
Each patient	<ul style="list-style-type: none"> <li>• A referent diabetologist, if applicable</li> <li>• Monthly podiatric examination</li> <li>• Podiatric risk stratification in the medical record</li> <li>• If new ulcer, refer to a specialized podiatric clinic</li> <li>• Adapted shoes if necessary</li> </ul>
Foot examination	<ul style="list-style-type: none"> <li>• personalized therapeutic education</li> <li>• history from the patient in regard to any foot-related issues (ulcer, amputation...)</li> <li>• systematic remove shoes</li> <li>• history of lower limb pain</li> <li>• examination of shoes to check for proper fit and appropriateness, and of the inside of the shoe to identify possible pressure points</li> <li>• appropriate shoes and socks, for example, socks without holes</li> <li>• foot deformities</li> <li>• poor foot hygiene, for example, improperly cut toenails, unwashed feet, superficial fungal infection, or unclean socks</li> <li>• palpation of pedal pulses, both the dorsalis pedis and posterior tibial pulses</li> <li>• foot sensory assessed with a Semmes-Weinstein 10-g monofilament</li> <li>• foot care knowledge and</li> <li>• reminder for a daily foot self-inspection</li> </ul>
Diabetes	<ul style="list-style-type: none"> <li>• HbA1c &lt;8%</li> <li>• continuous glucose monitoring if &gt;3 insulin injections per day</li> <li>• time in range &gt;50%</li> <li>• reduce the risk of hypoglycemia</li> </ul>

HbA1c, glycated hemoglobin.

failure. However, although the diabetic foot is usually targeted in prevention programs and ESRD is now equivalent to risk stratification category 3 of the IWGDF podiatric risk scale, there is still not enough strong data regarding the relation between CKD and the components of IWGDF podiatric risk. Should patients automatically advance from risk stratification 0 to 3 with the progression of diabetic nephropathy to ESRD despite the absence of history of foot ulcer or amputation? Research on this topic is important, as both chronic ESRD and dialysis are associated with an increased risk of diabetic foot and poor prognosis. This would significantly help in implementing optimized preventive programs.

### DISCLOSURE

All the authors declared no competing interests.

### REFERENCES

1. Armstrong DG, Boulton AJM, Bus SA. Diabetic foot ulcers and their recurrence. *N Engl J Med.* 2017;376:2367–2375. <https://doi.org/10.1056/NEJMra1615439>
2. Fosse-Edorh S, Mandereau-Bruno L, Hartemann-Heurtier A. Les hospitalisations pour complications podologiques chez les personnes diabétiques traitées pharmacologiquement. France en 2013. Published July 24, 2015. Accessed April 20,

2019. [http://beh.santepubliquefrance.fr/beh/2015/34-35/pdf/2015\\_34-35\\_4.pdf](http://beh.santepubliquefrance.fr/beh/2015/34-35/pdf/2015_34-35_4.pdf)
3. Morris AD, McAlpine R, Steinke D, et al. Diabetes and lower-limb amputations in the community: a retrospective cohort study. *Diabetes Care*. 1998;21:738–743. <https://doi.org/10.2337/diacare.21.5.738>
  4. Larsson J, Agardh CD, Apelqvist J, Stenström A. Long-term prognosis after healed amputation in patients with diabetes. *Clin Orthop*. 1998;(350):149–158.
  5. Gök Ü, Selek Ö, Selek A, Güdük A, Güner MÇ. Survival evaluation of the patients with diabetic major lower-extremity amputations. *Musculoskelet Surg*. 2016;100:145–148. <https://doi.org/10.1007/s12306-016-0399-y>
  6. Lavery LA, Peters EJ, Williams JR, Murdoch DP, Hudson A, Lavery DC. Reevaluating the way we classify the diabetic foot: restructuring the diabetic foot risk classification system of the International Working Group on the Diabetic Foot. *Diabetes Care*. 2008;31:154–156. <https://doi.org/10.2337/dc07-1302>
  7. Diabetic foot problems: prevention and management. Guidance NICE. National Institute for Health and Care Excellence. Published August 26, 2015. Accessed June 21, 2020. <https://www.nice.org.uk/guidance/ng19/chapter/Recommendations#treatment-2>
  8. Schaper NC, van Netten JJ, Apelqvist J, et al. Practical Guidelines on the prevention and management of diabetic foot disease (IWGDF 2019 update). *Diabetes Metab Res Rev*. 2020;36(suppl 1):e3266. <https://doi.org/10.1002/dmrr.3266>
  9. Lavery LA, Lavery DC, Hunt NA, Fontaine JL, Ndip A, Boulton AJ. Amputations and foot-related hospitalisations disproportionately affect dialysis patients. *Int Wound J*. 2015;12:523–526. <https://doi.org/10.1111/iwj.12146>
  10. Combe C, Albert JM, Bragg-Gresham JL, et al. The Burden of amputation among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Am J Kidney Dis*. 2009;54:680–692. <https://doi.org/10.1053/j.ajkd.2009.04.035>
  11. Kaminski MR, Raspovic A, McMahon LP, et al. Factors associated with foot ulceration and amputation in adults on dialysis: a cross-sectional observational study. *BMC Nephrol*. 2017;18:293. <https://doi.org/10.1186/s12882-017-0711-6>
  12. Morbach S, Furchert H, Gröblichhoff U, et al. Long-term prognosis of diabetic foot patients and their limbs. *Diabetes Care*. 2012;35:2021–2027. <https://doi.org/10.2337/dc12-0200>
  13. Fassett RG, Driver R, Healy H, et al. Comparison of markers of oxidative stress, inflammation and arterial stiffness between incident hemodialysis and peritoneal dialysis patients – an observational study. *BMC Nephrol*. 2009;10:8. <https://doi.org/10.1186/1471-2369-10-8>
  14. Pop-Busui R, Boulton AJM, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. *Diabetes Care*. 2017;40:136–154. <https://doi.org/10.2337/dc16-2042>
  15. Bourrier M, Ferguson TW, Embil JM, et al. Peripheral artery disease: its adverse consequences with and without CKD. *Am J Kidney Dis*. 2020;75:705–712. <https://doi.org/10.1053/j.ajkd.2019.08.028>
  16. Guerrero A, Montes R, Muñoz-Terol J, et al. Peripheral arterial disease in patients with stages IV and V chronic renal failure. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc*. 2006;21:3525–3531. <https://doi.org/10.1093/ndt/gfl470>
  17. Wattanakit K, Folsom AR, Selvin E, Coresh J, Hirsch AT, Weatherley BD. Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study. *J Am Soc Nephrol*. 2007;18:629–636. <https://doi.org/10.1681/ASN.2005111204>
  18. de Vinuesa SG, Ortega M, Martinez P, Goicoechea M, Campdera FG, Luño J. Subclinical peripheral arterial disease in patients with chronic kidney disease: prevalence and related risk factors. *Kidney Int Suppl*. 2005;93:S44–S47. <https://doi.org/10.1111/j.1523-1755.2005.09310.x>
  19. Yilmaz MI, Saglam M, Caglar K, et al. The determinants of endothelial dysfunction in CKD: oxidative stress and asymmetric dimethylarginine. *Am J Kidney Dis*. 2006;47:42–50. <https://doi.org/10.1053/j.ajkd.2005.09.029>
  20. O'Hare AM, Bacchetti P, Segal M, Hsu C, Johansen KL. Factors associated with future amputation among patients undergoing hemodialysis: results from the dialysis morbidity and mortality study waves 3 and 4. *Am J Kidney Dis*. 2003;41:162–170. <https://doi.org/10.1053/ajkd.2003.50000>
  21. Margolis DJ, Hofstad O, Feldman HI. Association between renal failure and foot ulcer or lower-extremity amputation in patients with diabetes. *Diabetes Care*. 2008;31:1331–1336. <https://doi.org/10.2337/dc07-2244>
  22. Morbach S, Quante C, Ochs HR, Gaschler F, Pallast JM, Knevels U. Increased risk of lower-extremity amputation among Caucasian diabetic patients on dialysis. *Diabetes Care*. 2001;24:1689–1690. <https://doi.org/10.2337/diacare.24.9.1689>
  23. Game FL, Chipchase SY, Hubbard R, Burden RP, Jeffcoate WJ. Temporal association between the incidence of foot ulceration and the start of dialysis in diabetes mellitus. *Nephrol Dial Transplant*. 2006;21:3207–3210. <https://doi.org/10.1093/ndt/gfl427>
  24. Ndip A, Rutter MK, Vileikyte L, et al. Dialysis treatment is an independent risk factor for foot ulceration in patients with diabetes and stage 4 or 5 chronic kidney disease. *Diabetes Care*. 2010;33:1811–1816. <https://doi.org/10.2337/dc10-0255>
  25. Game FL, Selby NM, McIntyre CW. Chronic kidney disease and the foot in diabetes - is inflammation the missing link. *Nephron Clin Pract*. 2013;123:36–40. <https://doi.org/10.1159/000351813>
  26. Pipili C, Grapsa E, Tripodaki ES, et al. Changes in skeletal muscle microcirculation after a hemodialysis session correlates with adequacy of dialysis. *Int J Nephrol Renov Dis*. 2015;8:59–64. <https://doi.org/10.2147/IJNRD.S68639>
  27. Beckert S, Sundermann K, Wolf S, et al. Haemodialysis is associated with changes in cutaneous microcirculation in diabetes mellitus. *Diabet Med*. 2009;26:89–92. <https://doi.org/10.1111/j.1464-5491.2008.02610.x>
  28. Gershater MA, Löndahl M, Nyberg P, et al. Complexity of factors related to outcome of neuropathic and neuro-ischaemic/ischaemic diabetic foot ulcers: a cohort study. *Diabetologia*. 2009;52:398–407. <https://doi.org/10.1007/s00125-008-1226-2>
  29. Krishnan AV, Kiernan MC. Uremic neuropathy: clinical features and new pathophysiological insights. *Muscle Nerve*. 2007;35:273–290. <https://doi.org/10.1002/mus.20713>

30. Aggarwal HK, Sood S, Jain D, Kaverappa V, Yadav S. Evaluation of spectrum of peripheral neuropathy in predialysis patients with chronic kidney disease. *Ren Fail.* 2013;35:1323–1329. <https://doi.org/10.3109/0886022X.2013.828261>
31. Colin JF, Elliot P, Ellis H. The effect of uraemia upon wound healing: an experimental study. *Br J Surg.* 1979;66:793–797. <https://doi.org/10.1002/bjs.1800661113>
32. Kato S, Chmielewski M, Honda H, et al. Aspects of immune dysfunction in end-stage renal disease. *Clin J Am Soc Nephrol.* 2008;3:1526–1533. <https://doi.org/10.2215/CJN.00950208>
33. Laaksonen S, Voipio-Pulkki L, Erkinjuntti M, Asola M, Falck B. Does dialysis therapy improve autonomic and peripheral nervous system abnormalities in chronic uraemia? *J Intern Med.* 2000;248:21–26. <https://doi.org/10.1046/j.1365-2796.2000.00690.x>
34. Ogura T, Makinodan A, Kubo T, Hayashida T, Hirasawa Y. Electrophysiological course of uraemic neuropathy in haemodialysis patients. *Postgrad Med J.* 2001;77:451–454. <https://doi.org/10.1136/pmj.77.909.451>
35. Sohn M-W, Budiman-Mak E, Lee TA, Oh E, Stuck RM. Significant J-shaped association between body mass index (BMI) and diabetic foot ulcers. *Diabetes Metab Res Rev.* 2011;27:402–409. <https://doi.org/10.1002/dmrr.1193>
36. Zhang SS, Tang ZY, Fang P, Qian HJ, Xu L, Ning G. Nutritional status deteriorates as the severity of diabetic foot ulcers increases and independently associates with prognosis. *Exp Ther Med.* 2013;5:215–222. <https://doi.org/10.3892/etm.2012.780>
37. Takahashi N, Morimoto S, Okigaki M, et al. Decreased plasma level of vitamin C in chronic kidney disease: comparison between diabetic and non-diabetic patients. *Nephrol Dial Transplant.* 2011;26:1252–1257. <https://doi.org/10.1093/ndt/gfq547>
38. Baylis C. Arginine, arginine analogs and nitric oxide production in chronic kidney disease. *Nat Clin Pract Nephrol.* 2006;2:209–220. <https://doi.org/10.1038/ncpneph0143>
39. Albina M, Jorge E. Nutrition and wound healing. *J Parenter Enter Nutr.* 1994;18:367–376.
40. Idris I, Tohid H, Muhammad NA, et al. Anaemia among primary care patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD): a multicentred cross-sectional study. *BMJ Open.* 2018;22, 8:e025125. doi:10.1136/bmjopen-2018-025125.
41. Wang V, Diamantidis CJ, Wylie J, Greer RC. Minding the gap and overlap: a literature review of fragmentation of primary care for chronic dialysis patients. *BMC Nephrol.* 2017;18:274. <https://doi.org/10.1186/s12882-017-0689-0>
42. Schouten RW, Haverkamp GL, Loosman WL, et al. Anxiety symptoms, mortality, and hospitalization in patients receiving maintenance dialysis: a cohort study. *Am J Kidney Dis Off J Natl Kidney Found.* 2019;74:158–166. <https://doi.org/10.1053/j.ajkd.2019.02.017>
43. Loosman WL, Rottier MA, Honig A, Siegert CEH. Association of depressive and anxiety symptoms with adverse events in Dutch chronic kidney disease patients: a prospective cohort study. *BMC Nephrol.* 2015;16:155. <https://doi.org/10.1186/s12882-015-0149-7>
44. Ndip A, Lavery LA, Boulton AJM. Diabetic foot disease in people with advanced nephropathy and those on renal dialysis. *Curr Diab Rep.* 2010;10:283–290. <https://doi.org/10.1007/s11892-010-0128-0>
45. Skolnik NS, Style AJ. Importance of early screening and diagnosis of chronic kidney disease in patients with type 2 diabetes. *Diabetes Ther.* 2021;12:1613–1630. <https://doi.org/10.1007/s13300-021-01050-w>
46. RAPPORT ANNUEL 2018 Réseau Épidémiologie et Information en Néphrologie. Accessed March 8, 2021. [https://www.agence-biomedecine.fr/IMG/pdf/rapport\\_rein\\_2018\\_v2.pdf](https://www.agence-biomedecine.fr/IMG/pdf/rapport_rein_2018_v2.pdf)
47. Gregg EW, Li Y, Wang J, et al. Changes in diabetes-related complications in the United States, 1990–2010. *N Engl J Med.* 2014;370:1514–1523. <https://doi.org/10.1056/NEJMc1406009>
48. Fernando DJS, Hutchison A, Veves A, Gokal R, Boulton AJM. Risk factors for non-ischæmic foot ulceration in diabetic nephropathy. *Diabet Med.* 1991;8:223–225. <https://doi.org/10.1111/j.1464-5491.1991.tb01576.x>
49. Hurley L, Kelly L, Garrow AP, et al. A prospective study of risk factors for foot ulceration: the West of Ireland Diabetes Foot Study. *Q J M.* 2013;106:1103–1110. <https://doi.org/10.1093/qjmed/hct182>
50. Mayeda L, Katz R, Ahmad I, et al. Glucose time in range and peripheral neuropathy in type 2 diabetes mellitus and chronic kidney disease. *BMJ Open Diabetes Res Care.* 2020;8:e000991. <https://doi.org/10.1136/bmjdcrc-2019-000991>
51. Brotman DJ, Bash LD, Qayyum R, et al. Heart rate variability predicts ESRD and CKD-related hospitalization. *J Am Soc Nephrol.* 2010;21:1560–1570. <https://doi.org/10.1681/ASN.2009111112>
52. Spallone V, Gambardella S, Maiello MR, et al. Relationship between autonomic neuropathy, 24-h blood pressure profile, and nephropathy in normotensive IDDM patients. *Diabetes Care.* 1994;17:578–584. <https://doi.org/10.2337/diacare.17.6.578>
53. Ndip A, Lavery LA, LaFontaine J, et al. High levels of foot ulceration and amputation risk in a multiracial cohort of diabetic patients on dialysis therapy. *Diabetes Care.* 2010;33:878–880. <https://doi.org/10.2337/dc09-2007>
54. Otte J, van Netten JJ, Woittiez A-JJ. The association of chronic kidney disease and dialysis treatment with foot ulceration and major amputation. *J Vasc Surg.* 2015;62:406–411. <https://doi.org/10.1016/j.jvs.2015.02.051>
55. Aragón-Sánchez J, Lázaro-Martínez JL, García-Álvarez Y, Morales EG, Hernández-Herrero MJ. Albuminuria is a predictive factor of in-hospital mortality in patients with diabetes admitted for foot disease. *Diabetes Res Clin Pract.* 2014;104:e23–e25. <https://doi.org/10.1016/j.diabres.2014.01.006>
56. Wolf G, Muller N, Busch M, et al. Diabetic foot syndrome and renal function in type 1 and 2 diabetes mellitus show close association. *Nephrol Dial Transplant.* 2009;24:1896–1901. <https://doi.org/10.1093/ndt/gfn724>
57. Kaminski MR, Raspovic A, McMahon LP, et al. Risk factors for foot ulceration and lower extremity amputation in adults with end-stage renal disease on dialysis: a systematic review and meta-analysis. *Nephrol Dial Transplant.* 2015;30:1747–1766. <https://doi.org/10.1093/ndt/gfv114>
58. Kaminski MR, Lambert KA, Raspovic A, et al. Risk factors for foot ulceration in adults with end-stage renal disease on dialysis: a prospective observational cohort study. *BMC*



- Nephrol.* 2019;20:423. <https://doi.org/10.1186/s12882-019-1594-5>
59. Aljarrah Q, Allouh MZ, Bakkar S, et al. Major lower extremity amputation: a contemporary analysis from an academic tertiary referral centre in a developing community. *BMC Surg.* 2019;19:170. <https://doi.org/10.1186/s12893-019-0637-y>
  60. Jupiter DC, Thorud JC, Buckley CJ, Shibuya N. The impact of foot ulceration and amputation on mortality in diabetic patients. I: from ulceration to death, a systematic review. *Int Wound J.* 2016;13:892–903. <https://doi.org/10.1111/iwj.12404>
  61. Hoffstad O, Mitra N, Walsh J, Margolis DJ. Diabetes, lower-extremity amputation, and death. *Diabetes Care.* 2015;38:1852–1857. <https://doi.org/10.2337/dc15-0536>
  62. van Baal J, Hubbard R, Game F, Jeffcoate W. Mortality associated with acute Charcot foot and neuropathic foot ulceration. *Diabetes Care.* 2010;33:1086–1089. <https://doi.org/10.2337/dc09-1428>
  63. Carrington AL, Shaw JE, Van Schie CHM, Abbott CA, Vileikyte L, Boulton AJM. Can motor nerve conduction velocity predict foot problems in diabetic subjects over a 6-year outcome period? *Diabetes Care.* 2002;25:2010–2015. <https://doi.org/10.2337/diacare.25.11.2010>
  64. Speckman RA, Frankenfield DL, Roman SH, et al. Diabetes is the strongest risk factor for lower-extremity amputation in new hemodialysis patients. *Diabetes Care.* 2004;27:2198–2203. <https://doi.org/10.2337/diacare.27.9.2198>
  65. Jones NJ, Chess J, Cawley S, Phillips AO, Riley SG. Prevalence of risk factors for foot ulceration in a general haemodialysis population. *Int Wound J.* 2013;10:683–688. <https://doi.org/10.1111/j.1742-481X.2012.01044.x>
  66. Eggers PW, Gohdes D, Pugh J. Nontraumatic lower extremity amputations in the Medicare end-stage renal disease population. *Kidney Int.* 1999;56:1524–1533. <https://doi.org/10.1046/j.1523-1755.1999.00668.x>
  67. Bruno G, Merletti F, Bargero G, et al. Estimated glomerular filtration rate, albuminuria and mortality in type 2 diabetes: the Casale Monferrato study. *Diabetologia.* 2007;50:941–948. <https://doi.org/10.1007/s00125-007-0616-1>
  68. Jeyaraman K, Berhane T, Hamilton M, Chandra AP, Falhammar H. Mortality in patients with diabetic foot ulcer: a retrospective study of 513 cases from a single Centre in the Northern Territory of Australia. *BMC Endocr Disord.* 2019;19:1. <https://doi.org/10.1186/s12902-018-0327-2>
  69. Ghanassia E, Villon L, Thuan dit Dieudonné J-F, Boegner C, Avignon A, Sultan A. Long-term outcome and disability of diabetic patients hospitalized for diabetic foot ulcers. *Diabetes Care.* 2008;31:1288–1292. <https://doi.org/10.2337/dc07-2145>
  70. Harding JL, Pavkov ME, Gregg EW, Burrows NR. Trends of nontraumatic lower extremity amputation in end-stage renal disease and diabetes, United States, 2000–2015. *Diabetes Care.* 2019;dc190296. <https://doi.org/10.2337/dc19-0296>
  71. Garcia M, Hernandez B, Ellington TG, et al. A lack of decline in major nontraumatic amputations in Texas: contemporary trends, risk factor associations, and impact of revascularization. *Diabetes Care.* 2019;42:1061–1066. <https://doi.org/10.2337/dc19-0078>
  72. McMurray SD, Johnson G, Davis S, McDougall K. Diabetes education and care management significantly improve patient outcomes in the dialysis unit. *Am J Kidney Dis.* 2002;40:566–575. <https://doi.org/10.1053/ajkd.2002.34915>
  73. Marn Pernat A, Peršič V, Usvyat L, et al. Implementation of routine foot check in patients with diabetes on hemodialysis: associations with outcomes. *BMJ Open Diabetes Res Care.* 2016;4:e000158. <https://doi.org/10.1136/bmjdc-2015-000158>
  74. Mcgrath N, Curran B. Recent commencement of dialysis is a risk factor for lower-extremity amputation in a high-risk diabetic population. *Diabetes Care.* 2000;23:412. <https://doi.org/10.2337/diacare.23.3.432>
  75. Lipscombe J, Jassal SV, Bailey S, Bargman JM, Vas S, Oreopoulos DG. Chiropody may prevent amputations in diabetic patients on peritoneal dialysis. *Perit Dial Int.* 2003;23:255–259.
  76. Foster AVM, Snowden S, Grenfell A, Watkins PJ, Edmonds ME. Reduction of gangrene and amputations in diabetic renal transplant patients: the role of a special foot clinic. *Diabet Med.* 1995;12:632–635. <https://doi.org/10.1111/j.1464-5491.1995.tb00555.x>
  77. Rubio JA, Jiménez S, Álvarez J. Clinical characteristics and mortality in patients treated in a Multidisciplinary Diabetic Foot Unit. *Endocrinol Diabetes Nutr (Engl).* 2017;64:241–249. <https://doi.org/10.1016/j.endinu.2017.02.012>
  78. Allison GM, Flanagan E. How ESKD complicates the management of diabetic foot ulcers: the vital role of the dialysis team in prevention, early detection, and support of multidisciplinary treatment to reduce lower extremity amputations. *Semin Dial.* 2020;33:245–253. <https://doi.org/10.1111/sdi.12875>